Commitments and Contingencies (Details Narrative)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
11 Months Ended |
12 Months Ended |
|
|
|
Mar. 29, 2023
USD ($)
shares
|
Feb. 28, 2023
USD ($)
|
Feb. 20, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
$ / shares
shares
|
Dec. 23, 2022
USD ($)
|
Aug. 26, 2022
USD ($)
|
Mar. 07, 2022
USD ($)
|
Dec. 15, 2021
USD ($)
|
Dec. 15, 2020
USD ($)
shares
|
Jan. 09, 2020
USD ($)
|
Apr. 18, 2019
USD ($)
$ / shares
shares
|
Jan. 18, 2019
USD ($)
ft²
|
Dec. 15, 2015
USD ($)
$ / shares
shares
|
Dec. 31, 2022
USD ($)
$ / shares
shares
|
Dec. 31, 2022
USD ($)
$ / shares
shares
|
Mar. 31, 2023
USD ($)
shares
|
Mar. 31, 2022
USD ($)
|
Dec. 12, 2022
USD ($)
shares
|
Dec. 31, 2022
USD ($)
$ / shares
shares
|
Dec. 31, 2022
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
shares
|
Mar. 10, 2023
shares
|
May 10, 2022
$ / shares
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payment description |
|
On
February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate
the L&F License or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000
of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash payment |
|
|
$ 398,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reclassification shares of common stock | shares |
|
|
|
65,783
|
|
|
|
|
|
|
|
|
|
65,783
|
65,783
|
0
|
|
|
65,783
|
65,783
|
|
|
|
| Reclassification shares of common stock value classified as temporary to permanent equity |
|
|
|
$ 331,331
|
|
|
|
|
|
|
|
|
|
$ 331,331
|
$ 331,331
|
|
|
|
$ 331,331
|
$ 331,331
|
|
|
|
| Financial Designation, Predecessor and Successor [Fixed List] |
|
|
|
Successor
|
|
|
|
|
|
|
|
|
|
|
Successor
|
Successor
|
Predecessor
|
Predecessor
|
|
Successor
|
Predecessor
|
|
|
| Operating lease asset amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 38,415
|
|
|
|
|
|
|
|
| License agreements up front cash payment |
|
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
|
|
|
|
|
|
|
|
|
| Aggregate milestone cash payments |
|
|
|
|
|
|
|
$ 500,000
|
$ 1,500,000
|
$ 1,000,000
|
$ 22,500,000
|
|
21,500,000
|
|
|
|
|
|
|
|
|
|
|
| Second license agreement milestone |
|
|
|
|
|
|
|
|
|
|
|
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock shares | shares |
|
|
|
9,016,139
|
|
|
|
|
|
|
|
|
|
9,016,139
|
9,016,139
|
9,211,922
|
|
|
9,016,139
|
9,016,139
|
|
|
|
| Aggregate common stock exercise price share | $ / shares |
|
|
|
$ 11.50
|
|
|
|
|
|
|
|
|
|
$ 11.50
|
$ 11.50
|
|
|
|
$ 11.50
|
$ 11.50
|
|
|
|
| Fair value of grant date excerisable |
|
|
|
|
|
|
|
|
|
|
|
|
$ 766,384
|
|
|
|
|
|
|
|
|
|
|
| License agreements payable upon commencement of Phase 2a |
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License agreements payable |
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash payment exercise price withheld |
|
|
|
|
|
|
|
|
|
$ 351,579
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate milestone cash payments, description |
|
|
|
|
|
|
|
|
|
|
the first
milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a
therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest
of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa
is required to pay sales royalties to the University of Miami between 3% and 6%.
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock shares | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
|
| Operating lease rent expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7,795
|
|
|
|
|
| Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock exercise price share | $ / shares |
|
|
|
$ 11.50
|
|
|
|
|
|
|
|
|
|
$ 11.50
|
$ 11.50
|
|
|
|
$ 11.50
|
$ 11.50
|
|
|
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of product sales |
|
|
|
|
|
|
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of product sales |
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
| Predecessor [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reclassification shares of common stock | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331,331
|
|
|
| Reclassification shares of common stock value classified as temporary to permanent equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 331,331
|
|
|
| Number of operating lease square feet | ft² |
|
|
|
|
|
|
|
|
|
|
|
3,500
|
|
|
|
|
|
|
|
|
|
|
|
| Sublease base rent |
|
|
|
|
|
|
|
|
|
|
|
$ 89,000
|
|
|
|
|
|
|
|
|
|
|
|
| Lease base rent lease commitment |
|
|
|
|
|
|
|
|
|
|
|
497,000
|
|
|
|
|
|
|
|
|
|
|
|
| Financial Designation, Predecessor and Successor [Fixed List] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Predecessor
|
Predecessor
|
|
|
Predecessor
|
|
|
| Operating lease rent expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 38,141
|
|
|
|
|
|
|
| License agreements up front cash payment |
|
|
|
|
|
|
|
|
|
|
$ 346,321
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock shares | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24,167,257
|
|
|
| Fair value of grant date excerisable |
|
|
|
|
|
|
|
|
|
|
$ 815,822
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of excerisable period |
|
|
|
|
|
|
|
|
|
|
|
|
period of five years
|
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock shares | shares |
|
|
|
|
|
|
|
|
|
|
400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sublease base rent lease commitment |
|
|
|
|
|
|
|
|
|
|
|
$ 497,000
|
|
|
|
|
|
|
|
|
|
|
|
| Operating lease rent expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 148,881
|
|
|
$ 148,125
|
|
|
| Predecessor [Member] | Research and Development Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of grant date excerisable |
|
|
|
|
|
|
|
|
|
|
$ 460,000
|
|
$ 306,411
|
|
|
|
|
|
|
|
|
|
|
| Common stock fair value |
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Predecessor [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock shares | shares |
|
|
|
|
|
|
|
|
|
|
600,000
|
|
878,947
|
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock exercise price share | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 2.30
|
|
$ 1.00
|
|
|
|
|
|
|
|
|
|
$ 3.20
|
| Fair value of grant date excerisable |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 153,324
|
|
|
|
|
|
|
|
|
|
| Aggregate common stock shares | shares |
|
|
|
351,578
|
|
|
|
|
175,789
|
|
|
|
351,579
|
351,578
|
351,578
|
|
|
6,406,210
|
351,578
|
351,578
|
|
|
|
| Aggregate common stock shares | shares |
|
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement [Member] | L&F Research LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
|
|
|
|
$ 1,500,000
|
$ 1,500,000
|
$ 1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from issuance of equity capital |
|
$ 30,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reclassification shares of common stock | shares |
65,783
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reclassification shares of common stock value classified as temporary to permanent equity |
$ 331,331
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Waiver A [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt forgiveness |
351,579
|
351,579
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash payment |
$ 648,421
|
$ 648,421
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
Mar. 31, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Waiver B [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash payment |
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
Jan. 31, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|